Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels
Yeri Kim, Jarred M Griffin, Mohd N Mat Nor, Jie Zhang, Peter S Freestone, Helen V Danesh-Meyer, Ilva D Rupenthal, Monica Acosta, Louise FB Nicholson, Simon J O'Carroll, Colin R Green
Neurotherapeutics | SPRINGER | Published : 2017
We thank Professor P.J. Donaldson for the generous loan of his electrophysiology equipment. This work was supported by a University of Auckland Doctoral Scholarship to Y.K. J.M.G was supported by the CatWalk Spinal Cord Injury Trust, and M.N.M.N by a PhD scholarship from the Ministry of Higher Education, Malaysia. C.R.G is a founding scientist of CoDa Therapeutics, Inc. USA, which holds intellectual property around the use of connexin channel modulators for the treatment of injury and disease. C.R.G and Y.K are named as inventors on patent application(s) related to uses of tonabersat. We acknowledge support from Auckland UniServices Ltd and the New Zealand Return on Science fund. C.R.G is the W&B Hadden Professor of Ophthalmology and Translational Research and acknowledges the generous support of W&B Hadden.